The concanavalin A model of acute hepatitis in mice

Laboratory Animals

Volumn 49, Issue , 2015, Pages 12-20

  Heymann, f ^a   Hamesch, k ^a   Weiskirchen, R ^a   Tacke, F ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

ConA; hepatitis; liver disease; mouse model; T cells

Indexed keywords

CONCANAVALIN A;

ACUTE DISEASE; ANIMAL; DISEASE MODEL; HEPATITIS; HUMAN; LABORATORY; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; STANDARDS;

ACUTE DISEASE; ANIMALS; CONCANAVALIN A; DISEASE MODELS, ANIMAL; GUIDELINES AS TOPIC; HEPATITIS; HUMANS; LABORATORY ANIMAL SCIENCE; MICE;

EID: 84979850744     PISSN: 00236772     EISSN: 17581117     Source Type: Journal    
DOI: 10.1177/0023677215572841     Document Type: Article

References (53)

1. Bies C Lehr C-M Woodley JF. Lectin-mediated drug targeting: history and applications. Adv Drug Deliv Rev 2004; 56: 425–435.
2. Asherson GL Ferluga J Janossy G. Non-specific cytotoxicity by T cells activated with plant mitogens in vitro and the requirement for plant agents during the killing reaction. Clin Exp Immunol 1973; 15: 573–589.
3. Lis H Sharon N. Lectins as molecules and as tools. Annu Rev Biochem 1986; 55: 35–67.
4. Roth RA Cassell DJ Maddux BA Goldfine ID. Regulation of insulin receptor kinase activity by insulin mimickers and an insulin antagonist. Biochem Biophys Res Commun 1983; 115: 245–252.
5. Sumner JB. The globulins of the jack bean, Canavalia ensiformis. J Biol Chem 1919; 37: 137–142.
6. Sumner JB Howell SF. Identification of hemagglutinin of jack bean with concanavalin A. J Bacteriol 1936; 32: 227–237.
7. Tiegs G Hentschel J Wendel A. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest 1992; 90: 196–203.
8. Nagaki M Muto Y Ohnishi H. Hepatic injury and lethal shock in galactosamine-sensitized mice induced by the superantigen staphylococcal enterotoxin B. Gastroenterology 1994; 106: 450–458.
9. Tiegs G Niehörster M Wendel A. Leukocyte alterations do not account for hepatitis induced by endotoxin or TNF alpha in galactosamine-sensitized mice. Biochem Pharmacol 1990; 40: 1317–1322.
10. Tiegs G Wolter M Wendel A. Tumor necrosis factor is a terminal mediator in galactosamine/endotoxin-induced hepatitis in mice. Biochem Pharmacol 1989; 38: 627–631.
11. McGill MR Williams CD Xie Y Ramachandran A Jaeschke H. Acetaminophen-induced liver injury in rats and mice: comparison of protein adducts, mitochondrial dysfunction, and oxidative stress in the mechanism of toxicity. Toxicol Appl Pharmacol 2012; 264: 387–394.
12. Baeck C Wehr A Karlmark KR. Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut 2012; 61: 416–426.
13. Karlmark KR Weiskirchen R Zimmermann HW. Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology 2009; 50: 261–274.
14. Heymann F Hammerich L Storch D. Hepatic macrophage migration and differentiation critical for liver fibrosis is mediated by the chemokine receptor C-C motif chemokine receptor 8 in mice. Hepatology 2012; 55: 898–909.
15. Jaeckel E Hardtke-Wolenski M Fischer K. The benefit of animal models for autoimmune hepatitis. Best Pract Res Clin Gastroenterol 2011; 25: 643–651.
16. Mizuhara H O'Neill E Seki N. T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6. J Exp Med 1994; 179: 1529–1537.
17. Margalit M Abu Gazala S Ghazala SA. Glucocerebroside treatment ameliorates ConA hepatitis by inhibition of NKT lymphocytes. Am J Physiol Gastrointest Liver Physiol 2005; 289: G917–G925.
18. Leist M Wendel A. A novel mechanism of murine hepatocyte death inducible by concanavalin A. J Hepatol 1996; 25: 948–959.
19. Küsters S Gantner F Künstle G Tiegs G. Interferon gamma plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin A. Gastroenterology 1996; 111: 462–471.
20. Leist M Gantner F Bohlinger I Tiegs G Germann PG Wendel A. Tumor necrosis factor-induced hepatocyte apoptosis precedes liver failure in experimental murine shock models. Am J Pathol 1995; 146: 1220–1234.
21. Trautwein C Rakemann T Brenner DA. Concanavalin A-induced liver cell damage: activation of intracellular pathways triggered by tumor necrosis factor in mice. Gastroenterology 1998; 114: 1035–1045.
22. Scaffidi C Fulda S Srinivasan A. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998; 17: 1675–1687.
23. Beraza N Malato Y Sander LE. Hepatocyte-specific NEMO deletion promotes NK/NKT cell- and TRAIL-dependent liver damage. J Exp Med 2009; 206: 1727–1737.
24. Tang G Minemoto Y Dibling B. Inhibition of JNK activation through NF-kappaB target genes. Nature 2001; 414: 313–317.
25. Luedde T Kaplowitz N Schwabe RF. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology 2014; 147: 765–783.e4.
26. Ogasawara J Watanabe-Fukunaga R Adachi M. Lethal effect of the anti-Fas antibody in mice. Nature 1993; 364: 806–809.
27. Arshad MI Piquet-Pellorce C L'Helgoualc'h A. TRAIL but not FasL and TNFα, regulates IL-33 expression in murine hepatocytes during acute hepatitis. Hepatology 2012; 56: 2353–2362.
28. Jouan-Lanhouet S Arshad MI Piquet-Pellorce C. TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation. Cell Death Differ 2012; 19: 2003–2014.
29. Lemasters JJ. Dying a thousand deaths: redundant pathways from different organelles to apoptosis and necrosis. Gastroenterology 2005; 129: 351–360.
30. Watanabe Y Morita M Akaike T. Concanavalin A induces perforin-mediated but not Fas-mediated hepatic injury. Hepatology 1996; 24: 702–710.
31. Hershkoviz R Bruck R Aeed H Shirin H Halpern Z. Treatment of concanavalin A-induced hepatitis in mice with low molecular weight heparin. J Hepatol 1999; 31: 834–840.
32. Yu Z Otsuka H Yamaguchi K. Roles of platelets and macrophages in the protective effects of lipopolysaccharide against concanavalin A-induced murine hepatitis. Biochim Biophys Acta 2011; 1812: 1069–1079.
33. Gantner F Leist M Lohse AW Germann PG Tiegs G. Concanavalin A-induced T-cell-mediated hepatic injury in mice: the role of tumor necrosis factor. Hepatology 1995; 21: 190–198.
34. Knolle PA Gerken G Loser E. Role of sinusoidal endothelial cells of the liver in concanavalin A-induced hepatic injury in mice. Hepatology 1996; 24: 824–829.
35. Matsumoto G Tsunematsu S Tsukinoki K-I. Essential role of the adhesion receptor LFA-1 for T cell-dependent fulminant hepatitis. J Immunol 2002; 169: 7087–7096.
36. Massaguer A Perez-Del-Pulgar S Engel P Serratosa J Bosch J Pizcueta P. Concanavalin-A-induced liver injury is severely impaired in mice deficient in P-selectin. J Leukoc Biol 2002; 72: 262–270.
37. Erhardt A Biburger M Papadopoulos T Tiegs G. IL-10, regulatory T cells, and Kupffer cells mediate tolerance in concanavalin A-induced liver injury in mice. Hepatology 2007; 45: 475–485.
38. Takamoto S Nakamura K Yoneda M Makino I. Gender-related differences in concanavalin A-induced liver injury and cytokine production in mice. Hepatol Res 2003; 27: 221–229.
39. Bernal W Wendon J. Acute liver failure. N Engl J Med 2013; 369: 2525–2534.
40. Trautwein C Rakemann T Malek NP Plümpe J Tiegs G Manns MP. Concanavalin A-induced liver injury triggers hepatocyte proliferation. J Clin Invest 1998; 101: 1960–1969.
41. Sass G Koerber K Bang R Guehring H Tiegs G. Inducible nitric oxide synthase is critical for immune-mediated liver injury in mice. J Clin Invest 2001; 107: 439–447.
42. Erhardt A Wegscheid C Claass B. CXCR3 deficiency exacerbates liver disease and abrogates tolerance in a mouse model of immune-mediated hepatitis. J Immunol 2011; 186: 5284–5293.
43. Hines IN Kremer M Isayama F. Impaired liver regeneration and increased oval cell numbers following T cell-mediated hepatitis. Hepatology 2007; 46: 229–241.
44. Volarevic V Milovanovic M Ljujic B. Galectin-3 deficiency prevents concanavalin A-induced hepatitis in mice. Hepatology 2012; 55: 1954–1964.
45. Tomiyama C Watanabe H Izutsu Y Watanabe M Abo T. Suppressive role of hepatic dendritic cells in concanavalin A-induced hepatitis. Clin Exp Immunol 2011; 166: 258–268.
46. Hammerich L, Warzecha KT, Stefkova M, et al. CREMα overexpression impairs function of hepatic myeloid derived suppressor cells and aggravates immune-mediated hepatitis in mice. Hepatology 2015 (in press).
47. Faul F Erdfelder E Buchner A Lang A-G. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods 2009; 41: 1149–1160.
48. Reeke GN Becker JW Edelman GM. The covalent and three-dimensional structure of concanavalin A. IV. Atomic coordinates, hydrogen bonding, and quaternary structure. J Biol Chem 1975; 250: 1525–1547.
49. Becker JW Reeke GN Wang JL Cunningham BA Edelman GM. The covalent and three-dimensional structure of concanavalin A. III. Structure of the monomer and its interactions with metals and saccharides. J Biol Chem 1975; 250: 1513–1524.
50. Carson M. Ribbons. Methods Enzymol 1997; 277: 493–505.
51. Wang Y, Feng D, Wang H, et al. STAT4 knockout mice are more susceptible to concanavalin A-induced T-cell hepatitis. Am J Pathol 2014; 6: 184: 1785–1794.
52. Burghardt S, Erhardt A, Claass B, et al. Hepatocytes contribute to immune regulation in the liver by activation of the Notch signaling pathway in T cells. J Immunol 2013; 11: 191: 5574–5582.
53. Streetz K, Fregien B, Plümpe J, et al. Dissection of the intracellular pathways in hepatocytes suggests a role for Jun kinase and IFN regulatory factor-1 in Con A-induced liver failure. J Immunol 2001; 1: 167: 514–523.